法尼基-X受体（FXR）作为动脉粥样硬化中有希望的药物靶标

Title:Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis

Volume: 24 Issue: 11

关键词: FXR，动脉粥样硬化，激动剂，胆汁酸，药物靶标，临床试验。

摘要: Background: Atherosclerosis (AS) is a major cause of death and morbidity in Western world and is strongly connected with atherogenic lipoproteins and inflammation. Bile acids (BA) act as activating signals of endogenous ligands such as Farnesoid-X receptor (FXR). Primary data indicate a potential role of FXR in AS. The therapeutic value of FXR ligands in AS is unknown.

Objective: With the present review, we analyzed the efficacy of FXR agonists as a therapeutic modalities against AS. In this aspect, we performed an electronic search through Pub- Med/MEDLINE database by using the key terms: FXR*, Farnesoid X receptor*, atherosclerosis*, bile acids* and agonism*.

Conclusion: According to our analysis, the FXR seems to be a promising therapeutic target in the atherosclerosis natural history. FXR agonism could exert protective effects in the development and evolution of AS. However, concomitant side effects such as the reduction of plasma HDL have been reported. Finally, results from undergoing clinical trials with synthetic FXR agonists will shed more light to the precise role of FXR agonism in AS treatment.

Cite this article as:

Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis, Current Medicinal Chemistry 2017; 24 (11) . https://dx.doi.org/10.2174/0929867324666170124151940

DOI https://dx.doi.org/10.2174/0929867324666170124151940	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X